Thus, PSMA-PET has improved specificity and sensitivity compared to standard imaging (CT, MRI, and bone scintigraphy), and also improves the detection of metastatic disease in biochemically recurrent PC with low serum PSA levels. This evidence concerns the gene KLK3 and pachyonychia congenita.